Immuno-Oncology Attracts Big Deal Dollars For Biotechs
This article was originally published in Start Up
Biotechs in the immuno-oncology space can’t operate in a vacuum. To attract funding and partners, their drug candidates must show potential to not only surpass available treatments, but also have the ability to work in tandem with them.
You may also be interested in...
Most of the deal's value is in milestone fees, but at $300m up front Bristol is giving IFM's Series A investors a 10X return for drug candidates that can inflame non-responsive tumors.
Despite having the lowest average likelihood of approval rating for US FDA regulatory decisions out of 18 disease groups, early-stage oncology deals continue to attract big price tags.
Private Company Edition: Lilly will open a third accelerator, this time in San Diego, and Fosun partnered with Treehill to help later-stage firms get over the finish line. Also, Flagship – after recent UK investments – signals its next fund will total $3bn. ArrivoBio and Alto Neuroscience raised $45m each.